A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis

OBJECTIVE: Tumour necrosis factor signalling via the receptor-interacting protein kinase 1 (RIPK1) pathway regulates colonic inflammation suggesting that RIPK1 inhibition may be a potential therapeutic target in ulcerative colitis (UC). This phase IIa, randomised, double-blind experimental medicine...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisel, Kathy, Scott, Nicola, Berger, Scott, Wang, Susanne, Brown, Kurt, Powell, Marcy, Broer, Matthijs, Watts, Clarissa, Tompson, Debra J, Burriss, Susan W, Hawkins, Simon, Abbott-Banner, Kathy, Tak, Paul Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365785/
https://www.ncbi.nlm.nih.gov/pubmed/34389633
http://dx.doi.org/10.1136/bmjgast-2021-000680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365785/
https://www.ncbi.nlm.nih.gov/pubmed/34389633
http://dx.doi.org/10.1136/bmjgast-2021-000680

Ejemplares similares